Home Medizin 99mTc-Maraciclatid hat Potenzial als nicht-invasiver Test für Endometriose im Frühstadium

99mTc-Maraciclatid hat Potenzial als nicht-invasiver Test für Endometriose im Frühstadium

von NFI Redaktion

Summary of preliminary results from patients with known or suspected endometriosis who were imaged with a SPECT-CT camera and subsequently underwent planned laparoscopic surgery, a minimally invasive surgical procedure to determine the presence, absence, and localization of endometrial lesions. Imaging findings were compared with surgical and histological reports, suggesting that 99mTc-Maraciclatid has potential as a non-invasive test for early-stage endometriosis.

In particular, these preliminary results indicate that 99mTc-Maraciclatid has the potential to:

  • Visualize superficial peritoneal endometriosis, which is located in the thin lining of the abdomen and pelvis and currently can only be accurately identified through surgery. This subtype accounts for approximately 80% of all endometriosis diagnoses. In patients in this study, 99mTc-Maraciclatid correctly identified superficial peritoneal endometriosis in patients where this endometriosis was confirmed laparoscopically in the early stages.
  • Highlight areas of activity in patients with deep endometriosis (often affecting organs such as the bladder, intestines, rectum, ovaries) and endometriomas (cysts commonly found in the ovaries).

The presentation also included a case study of a patient with superficial peritoneal endometriosis that was not identified by ultrasound but was visualized with 99mTc-Maraciclatid and later confirmed through laparoscopic surgery.

The ongoing study, which will involve a total of 20 to 25 patients, is led by Professor Christian Becker, Co-Director of the Endometriosis CaRe Centre in Oxford, and Professor Krina Zondervan, Head of Department at the Nuffield Department of Women’s and Reproductive Health, University of Oxford. It is expected to be completed later this year.

99mTc-Maraciclatid is a radioactively labeled tracer that binds with high affinity to the cell adhesion protein αvβ3 integrin and visualizes angiogenesis (formation of new blood vessels), which is known to be crucial for the development and growth of endometrial lesions.

David Hail, Chief Executive Officer of Serac Healthcare, said:

„These promising initial results demonstrate that Maraciclatid has real potential as a novel non-invasive method for diagnosing early-stage endometriosis. The ability to visualize the early stages of this disease is particularly important as it is not visible with other imaging techniques, contributing to the average delay of almost nine years to secure a diagnosis. We are very encouraged by these results and look forward to continuing this work with the world-leading specialists at the University of Oxford.“

„Endometriosis is a common condition affecting millions of women worldwide, causing pain and infertility. The current delay in diagnosis leads to prolonged suffering and uncertainty. Therefore, a novel imaging tool is urgently needed to assist healthcare professionals in identifying or ruling out the disease.“

Professor Christian Becker, Co-Director of the Endometriosis CaRe Centre in Oxford

Professor Krina Zondervan, Head of Department at the Nuffield Department of Women’s and Reproductive Health, University of Oxford, added:

„Superficial peritoneal endometriosis is the most common form of the disease, often affecting younger women where an earlier diagnosis could allow for intervention at an earlier stage, potentially changing outcomes significantly and improving prospects. At the Endometriosis CaRe Center at the University of Oxford, our studies focus on identifying new genetic, diagnostic, and therapeutic targets for endometriosis. We are pleased with the initial results of the DETECT study and look forward to recruiting more patients to consolidate the data.“

Related Posts

Adblock Detected

Please support us by disabling your AdBlocker extension from your browsers for our website.